Titre : Inconduite professionnelle

Inconduite professionnelle : Questions médicales fréquentes

Termes MeSH sélectionnés :

Scleroderma, Localized
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inconduite professionnelle : Questions médicales les plus fréquentes", "headline": "Inconduite professionnelle : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inconduite professionnelle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-17", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inconduite professionnelle" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Éthique", "url": "https://questionsmedicales.fr/mesh/D004989", "about": { "@type": "MedicalCondition", "name": "Éthique", "code": { "@type": "MedicalCode", "code": "D004989", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.350" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inconduite scientifique", "alternateName": "Scientific Misconduct", "url": "https://questionsmedicales.fr/mesh/D015871", "about": { "@type": "MedicalCondition", "name": "Inconduite scientifique", "code": { "@type": "MedicalCode", "code": "D015871", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.350.979.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Inconduite professionnelle", "alternateName": "Professional Misconduct", "code": { "@type": "MedicalCode", "code": "D028743", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Charles Piller", "url": "https://questionsmedicales.fr/author/Charles%20Piller", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Shokoh Varaei", "url": "https://questionsmedicales.fr/author/Shokoh%20Varaei", "affiliation": { "@type": "Organization", "name": "School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Nahid Dehghan Nayeri", "url": "https://questionsmedicales.fr/author/Nahid%20Dehghan%20Nayeri", "affiliation": { "@type": "Organization", "name": "Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Leila Sayadi", "url": "https://questionsmedicales.fr/author/Leila%20Sayadi", "affiliation": { "@type": "Organization", "name": "School of nursing & midwifery, Nursing and Midwifery Care Research Center, Tehran University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Akram Ghobadi", "url": "https://questionsmedicales.fr/author/Akram%20Ghobadi", "affiliation": { "@type": "Organization", "name": "School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. ghobadi_a57@yahoo.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Case of Linear Scleroderma in a Young Child: A Diagnosis Easily Missed in Primary Care.", "datePublished": "2023-05-19", "url": "https://questionsmedicales.fr/article/37202915", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.12659/AJCR.940148" } }, { "@type": "ScholarlyArticle", "name": "Atypical emphysema formation in a never-smoker with scleroderma-related interstitial pneumonia: a case report.", "datePublished": "2022-08-19", "url": "https://questionsmedicales.fr/article/36415340", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.11604/pamj.2022.42.295.29442" } }, { "@type": "ScholarlyArticle", "name": "Skin fibrosis associated with keloid, scleroderma and Jorge Lobo's disease (lacaziosis): An immuno-histochemical study.", "datePublished": "2022-10-01", "url": "https://questionsmedicales.fr/article/36183172", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/iep.12456" } }, { "@type": "ScholarlyArticle", "name": "Systemic sclerosis following COVID-19 infection with recurrent corticosteroid-induced scleroderma renal crisis.", "datePublished": "2023-03-17", "url": "https://questionsmedicales.fr/article/36931690", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bcr-2022-253735" } }, { "@type": "ScholarlyArticle", "name": "UVA1 irradiation attenuates collagen production via Ficz/AhR/MAPK signaling activation in scleroderma.", "datePublished": "2023-01-25", "url": "https://questionsmedicales.fr/article/36706594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.intimp.2023.109764" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Qualité, accès, évaluation des soins de santé", "item": "https://questionsmedicales.fr/mesh/D017530" }, { "@type": "ListItem", "position": 3, "name": "Éthique", "item": "https://questionsmedicales.fr/mesh/D004989" }, { "@type": "ListItem", "position": 4, "name": "Inconduite professionnelle", "item": "https://questionsmedicales.fr/mesh/D028743" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inconduite professionnelle - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inconduite professionnelle", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inconduite professionnelle", "description": "Comment identifier l'inconduite professionnelle ?\nQuels signes indiquent une inconduite ?\nQui peut signaler une inconduite ?\nQuels outils aident au diagnostic ?\nQuelles sont les conséquences d'un diagnostic tardif ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Scleroderma,+Localized&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inconduite professionnelle", "description": "Quels symptômes peuvent alerter sur une inconduite ?\nComment les patients réagissent-ils à l'inconduite ?\nQuels effets psychologiques l'inconduite a-t-elle ?\nY a-t-il des signes de stress chez le professionnel ?\nComment l'inconduite affecte-t-elle l'équipe médicale ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Scleroderma,+Localized&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inconduite professionnelle", "description": "Comment prévenir l'inconduite professionnelle ?\nQuel rôle joue la supervision dans la prévention ?\nComment impliquer les patients dans la prévention ?\nQuels outils technologiques aident à la prévention ?\nQuelle est l'importance de la culture organisationnelle ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Scleroderma,+Localized&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inconduite professionnelle", "description": "Quels traitements pour les victimes d'inconduite ?\nComment traiter l'inconduite chez un professionnel ?\nQuelles sanctions pour inconduite professionnelle ?\nComment réhabiliter un professionnel fautif ?\nQuels programmes de prévention existent ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Scleroderma,+Localized&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inconduite professionnelle", "description": "Quelles complications peuvent résulter de l'inconduite ?\nComment l'inconduite affecte-t-elle la réputation ?\nY a-t-il des conséquences légales ?\nComment l'inconduite impacte-t-elle le personnel ?\nQuelles sont les répercussions sur les patients ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Scleroderma,+Localized&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inconduite professionnelle", "description": "Quels facteurs augmentent le risque d'inconduite ?\nComment la formation influence-t-elle le risque ?\nQuel rôle joue l'environnement de travail ?\nLes antécédents personnels influencent-ils le risque ?\nComment la culture institutionnelle impacte-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Scleroderma,+Localized&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier l'inconduite professionnelle ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'inconduite se détecte par des plaintes, des comportements inappropriés ou des violations éthiques." } }, { "@type": "Question", "name": "Quels signes indiquent une inconduite ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des comportements tels que négligence, abus de pouvoir ou fraude peuvent indiquer une inconduite." } }, { "@type": "Question", "name": "Qui peut signaler une inconduite ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Tout membre du personnel médical, patient ou tiers peut signaler une inconduite professionnelle." } }, { "@type": "Question", "name": "Quels outils aident au diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des enquêtes, des audits et des évaluations de performance aident à diagnostiquer l'inconduite." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'un diagnostic tardif ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic tardif peut aggraver les dommages aux patients et compromettre la sécurité des soins." } }, { "@type": "Question", "name": "Quels symptômes peuvent alerter sur une inconduite ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des plaintes répétées de patients, des erreurs fréquentes ou un comportement inapproprié sont des symptômes." } }, { "@type": "Question", "name": "Comment les patients réagissent-ils à l'inconduite ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent ressentir de la méfiance, de l'anxiété ou de la détresse face à l'inconduite." } }, { "@type": "Question", "name": "Quels effets psychologiques l'inconduite a-t-elle ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "L'inconduite peut entraîner des traumatismes psychologiques chez les patients affectés." } }, { "@type": "Question", "name": "Y a-t-il des signes de stress chez le professionnel ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel en inconduite peut montrer des signes de stress, d'irritabilité ou d'isolement." } }, { "@type": "Question", "name": "Comment l'inconduite affecte-t-elle l'équipe médicale ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut créer des tensions, diminuer la confiance et affecter la collaboration au sein de l'équipe." } }, { "@type": "Question", "name": "Comment prévenir l'inconduite professionnelle ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par des formations éthiques, des codes de conduite et un environnement de travail sain." } }, { "@type": "Question", "name": "Quel rôle joue la supervision dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une supervision adéquate permet de détecter et de corriger les comportements inappropriés rapidement." } }, { "@type": "Question", "name": "Comment impliquer les patients dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent être formés à reconnaître et signaler des comportements inappropriés." } }, { "@type": "Question", "name": "Quels outils technologiques aident à la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de signalement en ligne et des applications de suivi des comportements peuvent aider." } }, { "@type": "Question", "name": "Quelle est l'importance de la culture organisationnelle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une culture organisationnelle positive favorise l'éthique et réduit les risques d'inconduite." } }, { "@type": "Question", "name": "Quels traitements pour les victimes d'inconduite ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les victimes peuvent bénéficier de thérapies psychologiques et de soutien émotionnel." } }, { "@type": "Question", "name": "Comment traiter l'inconduite chez un professionnel ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures disciplinaires, des formations et un suivi psychologique peuvent être nécessaires." } }, { "@type": "Question", "name": "Quelles sanctions pour inconduite professionnelle ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les sanctions peuvent inclure des avertissements, des suspensions ou des radiations de l'ordre." } }, { "@type": "Question", "name": "Comment réhabiliter un professionnel fautif ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La réhabilitation peut passer par des formations, du mentorat et un suivi régulier." } }, { "@type": "Question", "name": "Quels programmes de prévention existent ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des programmes de formation éthique et de sensibilisation sont mis en place pour prévenir l'inconduite." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de l'inconduite ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des dommages physiques, psychologiques et une perte de confiance dans le système de santé." } }, { "@type": "Question", "name": "Comment l'inconduite affecte-t-elle la réputation ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'inconduite peut gravement nuire à la réputation du professionnel et de l'établissement de santé." } }, { "@type": "Question", "name": "Y a-t-il des conséquences légales ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inconduite peut entraîner des poursuites judiciaires et des sanctions pénales." } }, { "@type": "Question", "name": "Comment l'inconduite impacte-t-elle le personnel ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut créer un environnement de travail toxique, affectant le moral et la productivité du personnel." } }, { "@type": "Question", "name": "Quelles sont les répercussions sur les patients ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent subir des erreurs médicales, des abus ou une détérioration de leur état de santé." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'inconduite ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, la surcharge de travail et un manque de supervision sont des facteurs de risque importants." } }, { "@type": "Question", "name": "Comment la formation influence-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Une formation insuffisante peut accroître le risque d'inconduite en diminuant la sensibilisation éthique." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement de travail ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement de travail toxique ou compétitif peut favoriser l'inconduite professionnelle." } }, { "@type": "Question", "name": "Les antécédents personnels influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de comportements inappropriés ou de problèmes psychologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Comment la culture institutionnelle impacte-t-elle le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Une culture institutionnelle laxiste envers l'éthique peut accroître le risque d'inconduite." } } ] } ] }

Sources (10000 au total)

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.

Among individuals with systemic sclerosis (SSc) randomized to cyclophosphamide (CYC) (n = 34) or hematopoietic stem cell transplantation (HSCT) (n = 33), we examined longitudinal trends of clinical, p... Assuming that data were missing at random, mixed-effects regression models were used to estimate longitudinal trends for clinical measures when comparing treatment groups. Results were compared to obs... Available observed means for pulmonary function tests appeared to improve over time in both arms. However, after accounting for participant loss, forced vital capacity in HSCT recipients increased by ... Longitudinal trends estimated from 2 statistical models affirm the efficacy of HSCT over CYC in severe SSc. Failure to account for early loss of participants may distort estimated clinical trends over...

Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up.

This study was undertaken to describe clinical manifestations in patients with Th/To antibody-positive systemic sclerosis (SSc) during long-term follow-up.... We performed a case-control study involving anti-Th/To antibody-positive patients with SSc who were newly referred to the University of Pittsburgh Medical Center and the Pittsburgh Scleroderma Center ... A total of 204 anti-Th/To antibody-positive SSc patients and 408 controls were identified. The cohort had a mean ± SD age of 52 ± 12.9 years, and 76% of individuals were women. Anti-Th/To antibody-pos... This is the largest cohort of patients with anti-Th/To antibody-positive SSc with long-term follow-up data. The very high rate (38%) and associated independent risk of anti-Th/To antibody-positive pat...

Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).

Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non-SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with... Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confi... Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36-1.60; P < 0... Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk....

Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized scleroderma Total Severity Scale (LoTSS).

Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcome, including contractures, hemi-atrophy, uveitis, and seizures. Despite improvements in treatme... LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multi-criteria decision analysis. Feasibility was assessed in larger Childhoo... LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by... We developed a new LS measure for assessing cutaneous and extracutaneous severity, and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the ...